

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT

PHASE III CLINICAL ON-SITE WORK COMPLETED FOR ITERATIVE PROCESS HIGH-POTENCY HUMAN DIPLOID CELL RABIES VACCINE

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

The iterative process high-potency human diploid cell rabies vaccine developed by the Group has successfully completed Phase III clinical on-site work. This marks the vaccine’s official entry into a new stage, laying a solid foundation for its future commercial launch.

This product, as an iterative upgraded human diploid cell rabies vaccine, is featured with super high-potency characteristics, and also marks a significant iterative upgrading in technology for the global rabies vaccine industry. Results from animal testing show that the Group’s human diploid cell rabies vaccine triggers a high level of antibodies that provide sufficient protection after immunization. Under the same dosage, the potency of the Group’s human diploid cell rabies vaccine is significantly higher than that of those marketed human diploid cell rabies vaccines.

Rabies is the disease with the highest fatality rate in the world; once the disease occurs, the fatality rate is nearly 100%. Currently, there is a lack of effective treatment for rabies in clinical practice, therefore, post-exposure prevention is crucial, and the main preventive measure is vaccination against human rabies. Compared with the traditional Vero cell rabies vaccines, human diploid cell rabies vaccine uses human diploid cells instead of Vero cells, which are homologous to humans and have a natural safety advantage. The human diploid cell rabies vaccine currently available in the market is 3 to 5 times more expensive than the Vero cell rabies vaccine, with higher product added value.

Compared with the traditional human diploid cell rabies vaccines of the first generation, the iterative process high-potency human diploid cell rabies vaccine developed by the Group has taken the lead in breaking through the technical bottlenecks of low virus titer and low yield in the traditional process. It has been optimized and innovated in the purification process with the product quality and safety significantly improved. This is not only a manifestation of the Company's R&D strength, but also a major breakthrough in the field of high-potency processes for rabies vaccines globally.

China is the largest rabies vaccine market globally. According to China Insights Consultancy, driven by product innovation and iteration, and increased accessibility to rabies vaccines, is projected to reach RMB14.8 billion by 2030. Compared with the number of traditional rabies vaccinations, this product developed by the Group can be vaccinated with either "five-needle approach" can also adopt the "simple four-needle approach" or "2-1-1 four-needle approach" for vaccination, which is more flexible and convenient. In accordance with the "Guidelines for the Prevention and Treatment of Rabies Exposure (2023 Edition)" (《狂犬病暴露預防處置工作規範》(2023年版)) issued by the National Disease Control and Prevention Administration and the National Health Commission, rabies prevention and treatment clinics should be equipped with at least two different types of rabies vaccines, the Group's product, by virtue of its iterative technological advantages and flexible vaccination regimens, is expected to become the first choice for vaccination institutions. The Group has completed the construction of an iterative-process high-potency human diploid cell rabies vaccine workshop that fully meets international standards, and completed the production of Phase III clinical trial samples on a commercial scale, and possesses the capability for large-scale production of the product.

Human diploid cell rabies vaccine is recommended by the WHO as the gold standard for rabies vaccines, and has been widely applied in many developed countries. As the world's second largest supplier of rabies vaccines, the Group is committed to leading the deep technical iteration and upgrading of rabies vaccines globally, providing the market with a series of rabies vaccine products with better quality and higher safety, further consolidating the Company's leading position in the global rabies vaccine field, and promoting the sustainable development of the Group. In the future, the approval of the product will further enrich the Company's product structure, synergize with its existing rabies vaccine series, and enhance its core competitiveness. As part of our global expansion strategy, this initiative will generate additional revenue, strengthen our market position, and add new momentum to the Company's sustained and steady development.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, January 15, 2026

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO as non-executive director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.